And it did so most harshly to Tarrytown, New York-based Regeneron, whose shares tumbled 10.1% on 7 March, or $34.25, before closing at $328.11, down $10.34, or 3.06%.
written on 08.03.2014
FDA raises cognitive concerns with PCSK9s; Amgen, Sanofi, Regeneron hit
